1620 Investment Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

1620 Investment Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-333	Closed	-$2.36K	–	717
2025 Q1	$2.36K	Hold	333	–	–	﹤0.01%	569
2024 Q4	$7.34K	Hold	333	–	–	0.01%	493
2024 Q3	$6.69K	Hold	333	–	–	﹤0.01%	500
2024 Q2	$5.8K	Hold	333	–	–	﹤0.01%	497
2024 Q1	$13.9K	Buy	+333	New	+$9.27K	0.01%	142
2023 Q4	–	Sell	-333	Closed	-$10.9K	–	155
2023 Q3	$10.9K	Hold	333	–	–	0.01%	141
2023 Q2	$19.4K	Buy	+333	New	+$17.1K	0.02%	138

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

1620 Investment Advisors's XFOR Position: Q2 2025 in Review

1620 Investment Advisors sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 333 shares — an estimated $2.36K sold.

1620 Investment Advisors first reported a position in XFOR in Q2 2023 and held it in 7 quarters. The position peaked at $19.4K in Q2 2023. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

1620 Investment Advisors reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
1620 Investment Advisors sold 333 X4 Pharmaceuticals shares in Q2 2025, an estimated $2.36K.
1620 Investment Advisors first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 7 quarters.
1620 Investment Advisors's X4 Pharmaceuticals position peaked at $19.4K in Q2 2023.
51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on 1620 Investment Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.